These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 16825812)

  • 21. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
    Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
    Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
    Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
    May M; Helke C; Nitzke T; Vogler H; Hoschke B
    Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
    Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F
    BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder.
    Dalbagni G; Parekh DJ; Ben-Porat L; Potenzoni M; Herr HW; Reuter VE
    BJU Int; 2007 Feb; 99(2):281-5. PubMed ID: 17155984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
    Dekairelle AF; Tombal B; Cosyns JP; Gala JL
    Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
    Mahnken A; Kausch I; Feller AC; Krüger S
    Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
    Cai T; Nesi G; Boddi V; Mazzoli S; Dal Canto M; Bartoletti R
    Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
    Yang TB; Zeng FH; Sun ZQ
    Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
    Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
    J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.
    Chatterjee SJ; Datar R; Youssefzadeh D; George B; Goebell PJ; Stein JP; Young L; Shi SR; Gee C; Groshen S; Skinner DG; Cote RJ
    J Clin Oncol; 2004 Mar; 22(6):1007-13. PubMed ID: 14981105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of 2004 and 1973 World Health Organization grading systems and their relationship to pathologic staging for predicting long-term prognosis in patients with urothelial carcinoma.
    Cao D; Vollmer RT; Luly J; Jain S; Roytman TM; Ferris CW; Hudson MA
    Urology; 2010 Sep; 76(3):593-9. PubMed ID: 20381131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of the current World Health Organization/International Society of Urologic Pathologists bladder neoplasm classification system on urine cytology results.
    Curry JL; Wojcik EM
    Cancer; 2002 Jun; 96(3):140-5. PubMed ID: 12115301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder.
    Popov Z; Hoznek A; Colombel M; Bastuji-Garin S; Lefrere-Belda MA; Bellot J; Abboh CC; Mazerolles C; Chopin DK
    Cancer; 1997 Oct; 80(8):1472-81. PubMed ID: 9338472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
    Krüger S; Lange I; Kausch I; Feller AC
    Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study of mutated p53 protein by immunohistochemistry in urothelial neoplasm of urinary bladder.
    Roychowdhury A; Dey RK; Bandyapadhyay A; Bhattacharya P; Mitra RB; Dutta R
    J Indian Med Assoc; 2012 Jun; 110(6):393-6. PubMed ID: 23360043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Significance of random biopsies of healthy mucosa in superficial bladder tumor].
    Fernández Gómez JM; Rodríguez Martínez JJ; Escaf Barmadah S; Pérez García J; García J; Casasola Chamorro J
    Arch Esp Urol; 2000 Nov; 53(9):785-97. PubMed ID: 11196385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 Gene mutations in superficial bladder cancer.
    Lorenzo Romero JG; Salinas Sánchez AS; Giménez Bachs JM; Sánchez Sánchez F; Escribano Martínez J; Hernández Millán IR; Segura Martín M; Virseda Rodríguez JA
    Urol Int; 2004; 73(3):212-8. PubMed ID: 15539839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative study of P 53, Bcl-2, and C-erbB-2 expression in low-grade papillary bladder tumors].
    Ramos Soler D; Navarro Fos S; Villamón Fort R; Gil Salom M; Llombart Bosch A
    Arch Esp Urol; 2003 Apr; 56(3):277-85. PubMed ID: 12768988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.